Quanterix Corp Dossier - Source-backed chat

Quanterix Corp

QTRXNASDAQ

SectorHealth Care

IndustryLife Sciences Tools & Services

Beta (adjusted)1.04

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $3.41Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $161.3M

Enterprise Value $117.1M

Shares Outstanding 50.9M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Quanterix Corp (QTRX) presents a complex, transition-phase investment profile. Following its acquisition of Akoya Biosciences in 2025, the company has successfully captured $85 million in annualized cost synergies, positioning it to target cash flow breakeven in the second half of 2026. However, underlying organic revenue trends remain highly challenged due to persistent spending headwinds in academic and pharmaceutical end-markets, resulting in a 21% organic decline in Simoa and a 26% decline in Spatial Biology during Q1 2026. While the stock trades at a highly depressed valuation of ~0.9x sales, reflecting deep market skepticism, near-term performance is heavily dependent on execution in the high-value Alzheimer's diagnostics market, specifically the pending FDA 510(k) clearance of its multi-marker blood test in H2 2026. Given the balance between significant cost-synergy achievements and weak organic top-line visibility, a Hold recommendation is warranted until clear signs of organic revenue stabilization and diagnostic commercialization traction emerge.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$4.33

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.3720%

The bear case centers on prolonged end-market weakness and execution delays. Academic and pharmaceutical funding constraints persist, causing further organic revenue contraction. The FDA 510(k) decision for the Alzheimer's blood test is delayed or rejected, and clinical utility studies fail to drive payor adoption. Cash burn remains elevated, preventing the company from reaching cash flow breakeven in H2 2026 and forcing a dilutive equity raise as the cash runway shrinks.

Base CaseCentral scenario

$4.0050%

The base case assumes Quanterix achieves its reaffirmed FY 2026 revenue guidance of $169M to $174M, representing flat to modest organic growth. Academic and pharma end-markets remain soft, but the company successfully reaches cash flow breakeven in the second half of 2026, exiting the year with approximately $100 million in cash and no debt. The FDA approves the Alzheimer's 510(k) application in late 2026, but direct testing revenues do not contribute meaningfully until 2027, keeping the stock range-bound near current levels as investors wait for commercial execution.

Bull CaseUpside scenario

$5.2530%

The bull case is driven by a successful pivot to clinical diagnostics and rapid adoption of the Simoa ONE platform. FDA 510(k) clearance of the multi-marker Alzheimer's blood test in H2 2026, combined with favorable Medicare pricing (CMS set an $897 reimbursement rate for LucentAD Complete), unlocks a multi-billion dollar clinical testing market. Operating leverage takes hold as the $85 million in captured Akoya synergies flow to the bottom line, driving the company to sustainable profitability and cash flow positivity ahead of expectations. Valuation re-rates from the depressed ~0.9x P/S toward the historical 5-year average of 4.5x.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Captured $85 million in annualized cost synergies from the Akoya Biosciences integration, significantly improving the operating cost structure.
Strong competitive moat in ultra-sensitive protein detection with the proprietary Simoa digital immunoassay platform.
Significant diagnostic catalyst with a pending FDA 510(k) decision on its multi-marker Alzheimer's blood test in H2 2026.
Reaffirmed path to cash flow breakeven in H2 2026, backed by a solid cash buffer of $102.6 million and no debt as of Q1 2026.

Key Investment Risks

Severe organic revenue declines (Simoa down 21% and Spatial Biology down 26% in Q1 2026) due to academic and pharma spending headwinds.
High customer concentration and exposure to volatile academic research budgets and NIH funding cycles.
Regulatory and commercialization risks associated with the clinical diagnostics pivot, where near-term revenue ramp is highly uncertain.
Historical track record of persistent net losses and cash burn, which has severely diluted shareholders over time.

Thesis Invalidation Triggers

Failure to achieve cash flow breakeven in the second half of 2026, leading to cash balances falling significantly below the targeted $100 million exit level.
FDA rejection or material delay of the 510(k) application for the multi-marker Alzheimer's blood test.
Continued double-digit organic revenue declines in core Simoa consumables and instruments over consecutive quarters.
A dilutive equity financing round in the next 12 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.